In-Hospital Initiation of Sacubitril/Valsartan: A New PARADIGM for Acute Decompensated Heart Failure?

J Cardiovasc Pharmacol. 2019 Jul;74(1):1-3. doi: 10.1097/FJC.0000000000000685.

Authors

Aldo Bonaventura^{1

2}, George F Wohlford³, Alessandra Vecchié^{1

2}, Benjamin W Van Tassel³, Antonio Abbate¹

Affiliations

¹ Division of Cardiology, Department of Internal Medicine, Pauley Heart Center, Virginia Commonwealth University, Richmond, VA.
² Department of Internal Medicine, First Clinic of Internal Medicine, University of Genoa, Genoa, Italy.
³ Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond, VA.

PMID: 31274835
DOI: 10.1097/FJC.0000000000000685

No abstract available

Publication types

Editorial

MeSH terms

Aminobutyrates / adverse effects
Aminobutyrates / therapeutic use*
Angiotensin II Type 1 Receptor Blockers / adverse effects
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Biphenyl Compounds
Clinical Trials as Topic
Drug Combinations
Evidence-Based Medicine
Heart Failure / diagnosis
Heart Failure / mortality
Heart Failure / physiopathology
Heart Failure / therapy*
Hospitalization
Humans
Neprilysin / antagonists & inhibitors
Protease Inhibitors / adverse effects
Protease Inhibitors / therapeutic use*
Recovery of Function
Tetrazoles / adverse effects
Tetrazoles / therapeutic use*
Treatment Outcome
Valsartan

Substances

Aminobutyrates
Angiotensin II Type 1 Receptor Blockers
Biphenyl Compounds
Drug Combinations
Protease Inhibitors
Tetrazoles
Valsartan
Neprilysin
sacubitril and valsartan sodium hydrate drug combination